Many people with Rheumatoid Arthritis (RA) may wish to have children. If this is you, please discuss this with your rheumatology team.

With careful treatment, most patients with RA can have healthy pregnancies and healthy babies.

Well-controlled RA improves the chance of healthy babies.

**Effect of RA on Pregnancy**
- Women with RA usually take longer to get pregnant.
- It’s uncertain whether there are increased miscarriages (pregnancy loss) in women with RA.
- Women with RA are more likely to have smaller babies, premature babies (born too early) and caesarean section.

**Effect of Pregnancy on RA**
- RA usually improves during pregnancy.
- However, up to 1 in 5 women with RA worsen in pregnancy.

Good control of RA before you fall pregnant will give the best chance of falling pregnant, having a healthy pregnancy and a healthy baby.

Some RA medications which work well can be safely taken during pregnancy. However, some RA medications should not be taken if planning a pregnancy.

**Labels and Categories**
- There is some confusion regarding government labelling of which medications are safe in pregnancy.

**Medications in Pregnancy**

**Pain management**
- Painkillers such as paracetamol and tramadol can be used if needed.
- Morphine-type medications (narcotics) used at high doses close to the birth may be harmful to the baby.
- Anti-inflammatories (NSAIDs) should not taken in the third trimester.

**Corticosteroids, e.g. prednisone/prednisolone**
- Risks to mothers include:
  - High blood pressure, gestational diabetes, bone thinning and infection
- Risks to babies include:
  - Prematurity (born too early), low birth weight and premature rupture of membranes
- Corticosteroids should only be used when other medications do not control the RA or cannot be used.
- Low doses (e.g. 5-7.5mg per day) can be used if the benefits outweigh the risk.
- If used, the dose should be as low as possible.
- It can be taken whilst breastfeeding, but if the dose is >20 mg/day, breastfeeding should be timed for 4 hours after dose.
- In men, use is not linked with infertility or harm to the baby.

**Disease Modifying Anti Rheumatic Drugs (DMARDs)**

**Hydroxychloroquine (HCQ)**
- Women who wish to become pregnant can use this medication.
- It can be continued during pregnancy.
- HCQ can be taken whilst breastfeeding.
- There is no information in men but it is likely to be safe.

**Sulfasalazine (SSZ)**
- Women who wish to become pregnant can use this medication with high dose folic acid supplementation (5mg a day) commenced 3 months before pregnancy and continued during pregnancy.
- It can be continued during pregnancy.
- SSZ can be taken whilst breastfeeding.
- As SSZ can cause reduced sperm movement, it should be stopped after 3 months of unsuccessfully trying for pregnancy.
Tumour Necrosis Factor Inhibitors (TNFi)
- Women who wish to become pregnant can use these medications.
- Check with your rheumatologist for the latest recommendations
- If continuing a TNFi in the third trimester is needed, it is wise to avoid live vaccines in your baby - please discuss with your rheumatologist and/or obstetric physician, and paediatrician.
- TNFi can be taken whilst breastfeeding.
- Use in men is probably safe but there’s limited information.

Non-TNFi biological DMARDs including abatacept, rituximab, tocilizumab
- Due to limited information, it is currently recommended to avoid these medications during pregnancy.
- If an unplanned pregnancy occurs, you should see a specialist in the field to discuss the pregnancy.
- Breastfeeding information is limited, but the amount in milk is likely to be very low, and it is probably destroyed in the baby’s gut.
- There is no information on which to base recommendation for fathering but they are likely to be safe.

Tofacitinib and baricitinib
- Due to limited information it is currently recommended to avoid this medication in pregnancy.
- If an unplanned pregnancy occurs the medication should be stopped and you should see a specialist in the field to discuss the pregnancy.
- Breastfeeding is not recommended.
- There is no information on which to base recommendation for fathering but they are likely to be safe.

DMARDs that should be AVOIDED during pregnancy
Methotrexate (MTX)
- This medication can harm the baby
- It should be stopped 3 months before trying to become pregnant
- If unplanned pregnancy occurs, MTX should be stopped immediately, 5 mg folic acid daily started and a specialist in the field should be seen to discuss the pregnancy.
- Breastfeeding should be avoided.
- Based on recent information, low-dose MTX appears safe with fathering.

Leflunomide (LEF)
- LEF is not recommended for use in pregnancy.
- It should be stopped 2 years before trying to fall pregnant or a cholestyramine washout is recommended.
- If unplanned pregnancy occurs, LEF should be stopped immediately, cholestyramine washout should be started and a specialist in the field should be seen to discuss the pregnancy.
- Avoid breastfeeding.
- Based on limited information LEF may be compatible with fathering but further studies to confirm are needed.

Remember with careful medical and obstetric management, most patients with RA can have successful pregnancies. If you have any questions please ask your rheumatologist.

More detailed information can be found at:
Arthritis Australia
American College of Rheumatology Website.
Your GP or other members of your care team may find the Australian Rheumatology Association (ARA) Guidance on Prescribing Medications for Rheumatic Diseases in Pregnancy helpful.

The information in this sheet has been obtained from various sources and has been reviewed by the Australian Rheumatology Association. It is intended as an educational aid. This information is not intended as medical advice for individual problems nor for making an individual assessment of the risks and benefits of taking a particular medicine. It can be reproduced in its entirety but cannot be altered without permission from the ARA. The NHMRC publication: How to present the evidence for consumers: preparation of consumer publications (2000) was used as a guide in developing this publication.